Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
Translational Oncology · 2025-05 · 55 · 102378
DOI: 10.1016/j.tranon.2025.102378 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Oncology, 2025-05. Verfasst von Razia Rahman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospital Research Foundation, Cancer Council New South Wales, Cancer Council Tasmania.
Abstract (Originalsprache)
Transcriptional control of gene expression is fundamental to all cellular processes. Conversely, transcriptional dysregulation is a hallmark of cancer. While this hallmark is a key driver of all malignancy-related process, it also represents a vulnerability that can be exploited therapeutically. Prostate cancer is a prime example of this phenomenon: it is characterised by aberrant transcription and treated with drugs that influence transcriptional pathways. Indeed, the primary oncogenic driver and therapeutic target of prostate cancer, the androgen receptor (AR), is a transcription factor. Moreover, a plethora of other transcriptional regulators, including transcriptional cyclin-dependent kinases (CDK7, CDK8 and CDK9), MYC and Bromodomain-containing protein 4 (BRD4), play prominent roles in disease progression. In this review, we focus on the roles of transcriptional CDKs in prostate cancer growth, metastasis and therapy resistance and discuss their interplay with AR, MYC and BRD4. Additionally, we explore recent advances in the therapeutic targeting of transcriptional CDKs and propose how these strategies could be effectively harnessed for the treatment of prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia.
- Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia; Flinders University, Freemasons Centre for Male Health and Wellbeing, Adelaide, Sout…
Förderung
- Hospital Research Foundation
- Cancer Council New South Wales
- Cancer Council Tasmania
- Cancer Council SA
- Cancer Australia
- Tasmanian Department of Health
- Flinders Foundation
Zitieren
APA
Rahman, R., & Selth, L. A. (2025). Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer. Translational Oncology, 55, 102378. https://doi.org/10.1016/j.tranon.2025.102378
Vancouver
Rahman R, Selth LA. Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer. Translational Oncology. 2025;55:102378. doi:10.1016/j.tranon.2025.102378
BibTeX
@article{Rahman2025,
author = {Rahman, Razia and Selth, Luke A},
title = {Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer},
journal = {Translational Oncology},
year = {2025},
volume = {55},
pages = {102378},
doi = {10.1016/j.tranon.2025.102378}
}
EUVIMED